Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
CARGO Therapeutics, Inc. (CRGX)
NASDAQ:CRGX
RESEARCH TOOLSreports
Holding CRGX?
Track your performance easily
CRGX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$13.56 - $33.92
Previous Close$16.23
Volume163.39K
Average Volume (3M)284.93K
Market Cap
$747.03M
Enterprise Value$370.77M
Total Cash (Recent Filing)$404.85M
Total Debt (Recent Filing)$28.58M
Price to Earnings (P/E)―
Beta2.35
Next Earnings
Nov 12, 2024EPS Estimate
-$1.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.55
Shares Outstanding46,027,727
10 Day Avg. Volume249,020
30 Day Avg. Volume284,930
Standard Deviation0.19
R-Squared0.16
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)1.82
Price to Sales (P/S)1282.88
Price to Cash Flow (P/CF)-4.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue641.46
Enterprise Value/Gross Profit1.28K
Enterprise Value/Ebitda-2.56
Forecast
1Y Price Target
$31.40Price Target Upside93.47% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
CARGO Therapeutics, Inc. News
PremiumCompany Announcements
CARGO Therapeutics Advances in Cancer Therapy Development
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentFiri-cel's efficacy results position it as a potentially more efficacious treatment post CD19-targeted CAR-T, addressing a substantial unmet need for patients who relapse.
Financial PerformanceCargo Therapeutics ended 2Q24 with roughly $443.5M in cash and cash equivalents, providing an operational runway through 2026 and past multiple key data catalysts.
Management And StrategyCARGO's management team has significant experience in CAR-Ts, bispecifics, and B cell cancers, which increases confidence in the company’s trial design.
Bears Say
Clinical TrialsNegative clinical results with firi-cel could adversely impact the stock's performance.
Competitive LandscapeIncreased competition from other cellular therapies and bispecifics currently in clinical development could challenge market share.
Regulatory ApprovalsInability to obtain regulatory approvals in a timely manner or at all poses a significant risk.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CRGX FAQ
What was CARGO Therapeutics, Inc.’s price range in the past 12 months?
CARGO Therapeutics, Inc. lowest stock price was $13.56 and its highest was $33.92 in the past 12 months.
What is CARGO Therapeutics, Inc.’s market cap?
Currently, no data Available
When is CARGO Therapeutics, Inc.’s upcoming earnings report date?
CARGO Therapeutics, Inc.’s upcoming earnings report date is Nov 12, 2024 which is 11 days ago.
How were CARGO Therapeutics, Inc.’s earnings last quarter?
CARGO Therapeutics, Inc. released its earnings results on Aug 12, 2024. The company reported -$1.02 earnings per share for the quarter, missing the consensus estimate of -$1.004 by -$0.016.
Is CARGO Therapeutics, Inc. overvalued?
According to Wall Street analysts CARGO Therapeutics, Inc.’s price is currently Undervalued.
Does CARGO Therapeutics, Inc. pay dividends?
CARGO Therapeutics, Inc. does not currently pay dividends.
What is CARGO Therapeutics, Inc.’s EPS estimate?
CARGO Therapeutics, Inc.’s EPS estimate is -$1.11.
How many shares outstanding does CARGO Therapeutics, Inc. have?
CARGO Therapeutics, Inc. has 46,027,725 shares outstanding.
What happened to CARGO Therapeutics, Inc.’s price movement after its last earnings report?
CARGO Therapeutics, Inc. reported an EPS of -$1.02 in its last earnings report, missing expectations of -$1.004. Following the earnings report the stock price went down -9.981%.
Which hedge fund is a major shareholder of CARGO Therapeutics, Inc.?
Among the largest hedge funds holding CARGO Therapeutics, Inc.’s share is Perceptive Advisors LLC. It holds CARGO Therapeutics, Inc.’s shares valued at 68M.
---
CARGO Therapeutics, Inc. Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$31.40 (93.47% Upside)
$31.40 (93.47% Upside)
Blogger Sentiment
Bullish
CRGX Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 1.0M Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Negative
20 days / 200 days
Momentum
9.14%
12-Months-Change
Fundamentals
Return on Equity
-69.81%
Trailing 12-Months
Asset Growth
447.20%
Trailing 12-Months
Company Description
CARGO Therapeutics, Inc.
CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.
---
CRGX Stock 12 Month Forecast
Average Price Target
$31.40
▲(93.47% Upside)
Technical Analysis
Adaptimmune Therapeutics
―
Black Diamond Therapeutics
―
Fate Therapeutics
―
Gritstone bio
―
Best Analysts Covering CRGX
1 Year
1 Year Success Rate
2/4 ratings generated profit
1 Year Average Return
-12.28%
reiterated a buy rating 11 days ago
Copying Biren Amin's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of -12.28% per trade.
---